Biologics

SurGenTec's OsteoFlo hydroputty synthetic bone graft earned 510(k) clearance from the FDA, the medtech company said March 7.

Bone Biologics, a company focused on spine fusion products, recently announced a $2 million public offering.

In February, Zimmer Biomet closed on the acquisition of orthobiologics company Embody for $155 million. Embody focuses on soft tissue healing, and its portfolio includes the Tapestry biointegrative implant for tendon healing and Tapestry RC implant for rotator cuff repair.

Regenerative medicine has been growing in orthopedics, and there's one important element that can push it forward in the field.

Here are four biologics updates Becker's has reported on since Dec. 13:

RTI Surgical signed an agreement to acquire Cook Biotech, according to a Jan. 8 news release. 

Kuros Biosciences hit three advancements for its MagnetOS portfolio, according to a Jan. 4 news release. 

Ossium Health's OssiGraft viable bone matrix allograft was used in its first patient case, according to a Dec. 14 news release.

Legislation has been introduced in the U.S. House that would require all bone graft material to be tested for active and latent tuberculosis. It would also expedite the process for developing a screening test, according to a Dec. 13 report…

Medical device company Alafair Biosciences has surpassed 12,000 implantations of its flagship product VersaWrap, the only class II medical device intended for use on tendon, ligament, skeletal muscle and peripheral nerve, including on nerve root in spine procedures.